Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunodeficiency Diseases Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Sep 28, 2026, 6:12 PM EDT
Completed No phase listed Observational

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

NCT00001255
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

NCT00002226
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
SU5416
Drug
Lead sponsor
SUGEN
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated No phase listed Observational

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus

NCT00321438
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Los Angeles, California • Tarzana, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 17, 2009 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)

NCT01106638
View directory record Official record
Conditions
Smoking, HIV Infections, AIDS
Interventions
Positively Smoke Free, Standard care
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional

Youth Engagement Study: Intervention to Increase HIV Treatment Engagement and Adherence for Young People Living With HIV

NCT03665532
View directory record Official record
Conditions
HIV/AIDS
Interventions
Youth Engagement in Services
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
16 Years to 35 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combinatorial Therapy to Induce an HIV Remission

NCT04357821
View directory record Official record
Conditions
HIV/AIDS
Interventions
Combination Intervention
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 67 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional Results available

An Extension of Protocol PRO 140_CD01 Study

NCT02355184
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140 350mg weekly subcutaneous (SC) injection.
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

NCT00002147
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Octanorm Subcutaneous IG in Patients With PID

NCT01888484
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
octanorm 16.5%
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

NCT06690047
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Ruconest
Biological
Lead sponsor
Bernstein Clinical Research Center
Other
Eligibility
14 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated No phase listed Observational

Immunoparalysis in Acute Kidney Injury After Cardiac Surgery

NCT03922958
View directory record Official record
Conditions
Acute Kidney Injury, Immune Deficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 4 Interventional Results available

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

NCT03842436
View directory record Official record
Conditions
HIV/AIDS, Substance Use Disorders, Adherence, Medication
Interventions
Digital pill, Truvada
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boylston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screen Smart: Using Digital Health to Improve HIV Screening and Prevention

NCT06003192
View directory record Official record
Conditions
HIV Infections
Interventions
Universal Opt-out HIV Screening
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 21 Years
Enrollment
63,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 28, 2026, 6:12 PM EDT
Not listed Phase 2 Interventional

MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia

NCT04887311
View directory record Official record
Conditions
Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
Interventions
MBM-01
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

NCT03968211
View directory record Official record
Conditions
Immune Deficiency
Interventions
Salmonella typhi polysaccharide vaccine
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

NCT00292981
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 Esterase Inhibitor
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
13
States / cities
Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 4 Interventional

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

NCT04249037
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

NCT02354937
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 28, 2026, 6:12 PM EDT